Lantern Pharma, Inc. ( (LTRN) ) has released its Q2 earnings. Here is a breakdown of the information Lantern Pharma, Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Lantern Pharma, Inc. is an artificial intelligence-focused biotechnology company dedicated to developing cancer therapies, leveraging its proprietary RADR® platform to streamline drug discovery and development in the oncology sector. In its latest earnings report for the quarter ending June 30, 2025, Lantern Pharma highlighted its continued focus on advancing its three clinical-stage oncology product candidates and its Antibody Drug Conjugate (ADC) program. The company reported a net loss of $4.33 million for the quarter, a slight improvement from the $4.96 million loss in the same period last year, reflecting ongoing investments in research and development. Key financial metrics showed a decrease in total assets to $17.42 million from $25.57 million at the end of 2024, primarily due to reductions in cash and marketable securities. Despite the financial losses, Lantern Pharma continues to advance its strategic initiatives, including the development of its LP-300, LP-184, and LP-284 drug candidates, as well as expanding its RADR® platform’s capabilities. Looking ahead, the company remains focused on securing additional funding to support its research and development efforts and is exploring various financing options to sustain its operations into 2026.